French multicentre observational study on SARS-CoV-2 infections intensive care initial management: the FRENCH CORONA study - 01/09/21
, Olivier Collange c, Myriam Mezzarobba d, Osama Abou-Arab e, Lauranne Teule f, Marc Garnier g, Clément Hoffmann h, Laurent Muller a, b, Jean-Yves Lefrant a, b, Pierre Grégoire Guinot i, Emmanuel Novy j, Paul Abraham k, Thomas Clavier l, Jérémy Bourenne m, Guillaume Besch n, Laurent Favier o, Michel Fiani p, Alexandre Ouattara q, Olivier Joannes-Boyau q, Marc-Olivier Fischer r, Marc Leone s, Younes Ait Tamlihat t, Julien Pottecher u, Pierre-Yves Cordier v, Philippe Aussant w, Mouhamed Djahoum Moussa x, Etienne Hautin y, Marine Bouex z, Jean-Michel Julia aa, Julien Cady bb, Marc Danguy Des Déserts cc, Nicolas Mayeur dd, Thibault Mura d, Bernard Allaouchiche eefor the AZUREA group
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Abstract |
Aim |
Describing acute respiratory distress syndrome patterns, therapeutics management, and outcomes of ICU COVID-19 patients and indentifying risk factors of 28-day mortality.
Methods |
Prospective multicentre, cohort study conducted in 29 French ICUs. Baseline characteristics, comorbidities, adjunctive therapies, ventilatory support at ICU admission and survival data were collected.
Results |
From March to July 2020, 966 patients were enrolled with a median age of 66 (interquartile range 58–73) years and a median SAPS II of 37 (29–48). During the first 24 h of ICU admission, COVID-19 patients received one of the following respiratory supports: mechanical ventilation for 559 (58%), standard oxygen therapy for 228 (24%) and high-flow nasal cannula (HFNC) for 179 (19%) patients. Overall, 721 (75%) patients were mechanically ventilated during their ICU stay. Prone positioning and neuromuscular blocking agents were used in 494 (51%) and 460 (48%) patients, respectively. Bacterial co-infections and ventilator-associated pneumonia were diagnosed in 79 (3%) and 411 (43%) patients, respectively. The overall 28-day mortality was 18%. Age, pre-existing comorbidities, severity of respiratory failure and the absence of antiviral therapy on admission were identified as independent predictors of 28-day outcome.
Conclusion |
Severity of hypoxaemia on admission, older age (> 70 years), cardiovascular and renal comorbidities were associated with worse outcome in COVID-19 patients. Antiviral treatment on admission was identified as a protective factor for 28-day mortality. Ascertaining the outcomes of critically ill COVID-19 patients is crucial to optimise hospital and ICU resources and provide the appropriate intensity level of care.
El texto completo de este artículo está disponible en PDF.Abbreviations : ICU, LOS, ARDS, SAPS II, SOFA, RRT, ECMO, IMV, NIV, HFNC
Keywords : Viral pneumonia, Outcome, COVID-19, Management
Esquema
Vol 40 - N° 4
Artículo 100931- août 2021 Regresar al número
Artículo precedente
- What is the most adequate non-invasive oxygen support for acute hypoxaemic respiratory failure due to COVID-19?
- Jean-Pierre Frat, Arnaud W. Thille, François Arrivé, Manel Lujan, Jordi Rello
- Deployment of a mobile military ICU embedded in a civilian hospital during the second COVID-19 outbreak in Mayotte, France
- Quentin Mathais, Astrée Swiech, Gaël De Rocquigny, Chloé Thill, Philippe Aries
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.